Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics, Genentech Pen Drug Discovery Alliance

NEW YORK, Dec. 18 - Lexicon Genetics over the next three years will work with Genentech to discover new therapeutic proteins and antibody targets, the companies said today.


Genentech will identify genes of interest while Lexicon will characterize their physiology. Genentech retains some rights to develop and commercialize potential therapeutics; Lexicon will get a package worth up to $39 million, including upfront payments, performance-based payments and a convertible loan.

Additionally, Lexicon is entitled to pre-commercialization milestone payments and royalties on any products, while Genentech obtained an internal use sublicense from Lexicon covering its gene-targeting technology.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.